Lin Yi, Jiang Tao, Zhou Kaijia, Xu Li, Chen Baoshi, Li Guilin, Qiu Xiaoguang, Jiang Tianzi, Zhang Wei, Song Sonya W
LIAMA Center for Computational Medicine, National Laboratory of Pattern Recognition, Institute of Automation, Chinese Academy of Sciences, Beijing, China.
Neuro Oncol. 2009 Oct;11(5):468-76. doi: 10.1215/15228517-2008-114. Epub 2009 Jan 22.
Insulin-like growth factor binding protein 2 (IGFBP-2) is a malignancy-associated protein measurable in tumors and blood. Increased IGFBP-2 is associated with shortened survival of advanced glioma patients. Thus, we examined plasma IGFBP-2 levels in glioma patients and healthy controls to evaluate its value as a plasma biomarker for glioma. Plasma IGFBP-2 levels in 196 patients with newly diagnosed glioma and 55 healthy controls were analyzed using an IGFBP-2 ELISA kit. Blood was collected before surgery, after two-cycle adjuvant chemotherapy, and at recurrence. Plasma IGFBP-2 levels were correlated with disease-free survival (DFS) using Cox regression analyses. We found that preoperative plasma IGFBP-2 levels were significantly higher in high-grade glioma patients (n = 43 for grade III glioma; n = 72 for glioblastoma multiforme [GBM]) than in healthy controls (n = 55; p < 0.001) and low-grade (grade II) glioma patients (n = 81; p < 0.001). No significant differences in preoperative plasma IGFBP-2 levels were observed between grade III glioma and GBM patients or between grade II glioma patients and healthy controls. After recurrence, plasma IGFBP-2 levels were significantly increased in GBM patients (n = 26; p < 0.001). Preoperative plasma IGFBP-2 levels were significantly correlated with DFS in GBM patients (hazard ratio, 1.404; 95% confidence interval, 1.078-1.828; p = 0.012). We conclude that preoperative plasma IGFBP-2 levels are significantly higher in high-grade glioma patients than in low-grade glioma patients and healthy subjects, and are significantly correlated with recurrence and DFS in patients with GBM. Longitudinal studies with a larger study population are needed to confirm these findings.
胰岛素样生长因子结合蛋白2（IGFBP - 2）是一种可在肿瘤和血液中检测到的与恶性肿瘤相关的蛋白。IGFBP - 2升高与晚期胶质瘤患者生存期缩短相关。因此，我们检测了胶质瘤患者和健康对照者的血浆IGFBP - 2水平，以评估其作为胶质瘤血浆生物标志物的价值。使用IGFBP - 2 ELISA试剂盒分析了196例新诊断胶质瘤患者和55例健康对照者的血浆IGFBP - 2水平。在手术前、两周期辅助化疗后及复发时采集血液。使用Cox回归分析血浆IGFBP - 2水平与无病生存期（DFS）的相关性。我们发现，高级别胶质瘤患者（III级胶质瘤43例；多形性胶质母细胞瘤[GBM]72例）术前血浆IGFBP - 2水平显著高于健康对照者（55例；p < 0.001）和低级别（II级）胶质瘤患者（81例；p < 0.001）。III级胶质瘤患者和GBM患者之间或II级胶质瘤患者与健康对照者之间术前血浆IGFBP - 2水平无显著差异。复发后，GBM患者（26例；p < 0.001）血浆IGFBP - 2水平显著升高。GBM患者术前血浆IGFBP - 2水平与DFS显著相关（风险比，1.404；95%置信区间，1.078 - 1.828；p = 0.012）。我们得出结论，高级别胶质瘤患者术前血浆IGFBP - 2水平显著高于低级别胶质瘤患者和健康受试者，且与GBM患者的复发和DFS显著相关。需要更大研究人群的纵向研究来证实这些发现。
